Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure by John D. Sheppard et al.
REVIEW
Impact of the Topical Ophthalmic Corticosteroid
Loteprednol Etabonate on Intraocular Pressure
John D. Sheppard . Timothy L. Comstock . Megan E. Cavet
Received: February 5, 2016 / Published online: March 17, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Corticosteroids are a mainstay therapeutic
option for the treatment of ocular
inflammation. However, safety remains a
concern for clinicians, particularly with
long-term use. Though highly effective at
suppressing inflammatory and allergic
responses, topical ophthalmic corticosteroids
carry an inherent risk of side effects, including
elevated intraocular pressure (IOP), a risk factor
for the development of glaucoma. The
corticosteroid loteprednol etabonate (LE)
contains an ester rather than a ketone at the
C-20 position, minimizing the potential for side
effects, including IOP elevation. In early pivotal
clinical trials of LE ophthalmic suspension for
conjunctivitis (allergic, giant papillary), anterior
uveitis, and post-operative inflammation, LE
had minimal impact on IOP over short-term
(\28 days) and long-term (C28 days) use. Since
then, new LE formulations—including a gel, an
ointment, and a suspension of LE in
combination with tobramycin—have become
commercially available. Multiple studies
evaluating the safety and efficacy of LE for
inflammatory conditions have been reported,
including those requiring longer-term
treatment such as photorefractive keratectomy,
corneal transplantation, and dry eye disease.
We review the available published data on the
effect of LE on IOP and report on the
cumulative incidence of clinically significant
IOP elevations (C10 mm Hg from baseline) with
short-term and long-term LE use. In all studies,
LE consistently demonstrated a low propensity
to elevate IOP, regardless of formulation, dosage
regimen, or treatment duration, including in
known steroid responders. The cumulative
proportion of patients exhibiting clinically
significant IOP increases was 0.8% (14/1725
subjects) in studies evaluating short-term LE
treatment and 1.5% (21/1386 subjects) in
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/0C44
F0606370E8F1.
J. D. Sheppard
Department of Ophthalmology, Eastern Virginia
Medical School, Norfolk, VA, USA
T. L. Comstock
Rochester, NY, USA
M. E. Cavet (&)
Medical Affairs, Bausch ? Lomb, Rochester,
NY, USA
e-mail: Megan.Cavet@bausch.com
Adv Ther (2016) 33:532–552
DOI 10.1007/s12325-016-0315-8
long-term studies. Furthermore, use of LE was
associated with significantly lower rates of IOP
elevation C10 mm Hg as compared to
prednisolone acetate or dexamethasone (when
used in combination with tobramycin). The
cumulative data to date substantiates a
favorable IOP-safety profile for LE with both
short-term and long-term use.
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INTRODUCTION
Topical corticosteroids are widely used to treat
inflammatory conditions of the ocular surface
and the anterior segment. Acting through the
cytosolic glucocorticoid receptors and exerting
their effects predominantly at the genomic
level, corticosteroids possess broad
mechanisms of action and potent
anti-inflammatory activity [1–3]. By inhibiting
upstream phospholipase A2, they block both
the cyclooxygenase and lipoxygenase pathways
of the inflammatory cascade and thus prevent
formation of all eicosanoids [2, 3]. In addition,
they are known to inhibit inflammatory
cytokines, chemokines, adhesion molecules,
and other inflammatory mediators [1, 4].
These pathways are involved in the
progression of many ocular surface and
anterior segment inflammatory conditions,
including post-surgical inflammation, anterior
uveitis, blepharitis, and dry eye. Additionally,
corticosteroids reduce synthesis of histamine,
stabilize cell membranes, and inhibit
degranulation of mast cells, making topical
corticosteroids an effective treatment for
ocular allergic inflammatory conditions [5, 6].
In addition to their therapeutic effects,
corticosteroids can produce a number of
adverse side effects, including cataract
formation, increased susceptibility to microbial
infection, delayed wound healing, and, the
focus of this review, intraocular pressure (IOP)
elevation [7, 8]. Corticosteroid-induced ocular
hypertension may occur with any mode of
administration, but is much more common
with topical corticosteroids than with
corticosteroid systemic therapies [9–11].
Besides the active moiety itself, factors
contributing to the IOP-raising potential of a
specific topical corticosteroid include ocular
pharmacokinetics, dosage, and treatment
duration [7, 12]. IOP elevation has been found
to be common with older corticosteroids such
as dexamethasone and prednisolone [12, 13].
Difluprednate, one of the newer corticosteroids
and a difluorinated derivative of prednisolone,
also demonstrates a higher propensity to raise
IOP in comparison to corticosteroids such as LE
and rimexolone [12]. It has long been
recognized that, in the general adult
population, about one-third will experience
IOP elevations of 6–15 mm Hg (moderate
responders) and 4–6% will experience IOP
elevations [15 mm Hg (high responders)
following 4–6 weeks of topical corticosteroid
therapy [14–16]. These ‘‘steroid responders’’
usually have predisposing factors, such as a
family history of glaucoma, diabetes mellitus,
myopia, or younger age [9, 17–20]. When this
IOP increase persists, patients may develop
glaucomatous optic nerve damage and
irreversible vision loss [7, 9, 19].
The exact mechanism of steroid-induced IOP
elevation is not fully understood. Genetics
clearly play a role in steroid-induced
glaucoma. Studies have shown that
corticosteroids can cause multiple
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physiological changes in the main aqueous
humor outflow pathway, the trabecular
meshwork. These changes include the
formation of cross-linked actin fibers,
increased deposition of extracellular matrix
material, and inhibition of cell phagocytosis,
which together result in an increased resistance
to aqueous outflow and thus elevation of IOP [9,
12]. Multiple genes are upregulated in
glaucoma, with the most well studied being
myocilin which encodes a 55 kDa secreted
protein [9]. Mutations in the myocilin gene
are linked to both juvenile and adult-onset
glaucoma. The protein myocilin is upregulated
in trabecular meshwork cells exposed to
steroids. However, the precise
mechanism(s) by which myocilin causes
glaucoma remains to be elucidated [9].
Loteprednol etabonate (LE) is unique among
corticosteroids in that the drug molecule
incorporates a metabolically labile moiety
which allows rapid metabolism and
degradation following glucocorticoid receptor
activation, thereby imparting a lower risk of
side effects [21–23]. Unlike other ophthalmic
corticosteroids, LE contains a chloromethyl
ester instead of a ketone moiety at the carbon
20 (C-20) position of the prednisolone acetate
(PA) core structure (Fig. 1). The metabolically
labile C-20 ester group undergoes
predictable hydrolysis by endogenous esterases
into inactive metabolites (Fig. 1). In addition,
LE is highly lipophilic and binds the
glucocorticoid receptor with 4.3-fold greater
affinity than dexamethasone [24]. LE also
retains the high potency of prednisolone, with
an anti-inflammatory efficacy 20-fold higher
than hydrocortisone [22]. These attributes
enable LE to penetrate the ocular tissues
including the conjunctiva, cornea, and
iris-ciliary body, bind to the glucocorticoid
receptor, and exert potent anti-inflammatory
effects, with minimal propensity for side effects
[21–23, 25].
LE was approved in 1998 by the US Food and
Drug Administration (FDA) in two ophthalmic
formulations. Lotemax ophthalmic
suspension 0.5% (Bausch ? Lomb, Tampa, FL,
USA) is indicated for the treatment of various
ocular surface and anterior segment
inflammatory conditions and postoperative
inflammation following ocular surgery. Alrex
ophthalmic suspension, 0.2% (Bausch ? Lomb)
is indicated specifically for temporary relief of
the signs and symptoms of seasonal allergic
conjunctivitis. Both products were well
tolerated and had minimal impact on IOP in
phase III randomized clinical trials performed
for the original US FDA approval of LE [26–33].
Novack and colleagues [34] evaluated the
Fig. 1 Molecular structure of LE and its inactive
metabolites. LE is a 17b-chloromethylester derivative of
D1-cortienic acid, an inactive metabolite of prednisolone;
LE also has a 17a-etabonate moiety. LE undergoes rapid
deesteriﬁcation to the inactive D1-cortienic acid after
exerting its effect. LE loteprednol etabonate
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potential of LE to elevate IOP with long-term
use across all preapproval LE clinical studies. A
total of 1648 healthy volunteers and patients
with ocular inflammation or allergy who were
treated with LE (0.2% or 0.5%), PA 1%, or
vehicle for C28 days were included in this
retrospective meta-analysis. Significant IOP
elevation (defined as C10 mm Hg above
baseline) occurred in 1.7% (15/901) of subjects
receiving LE, in 6.7% (11/164) of subjects
receiving PA 1%, and in 0.5% (3/583) of
subjects receiving vehicle. LE 0.2% had a
similar effect upon IOP as vehicle, with one
subject developing IOP elevation in each
treatment group (0.8% or 1/133 for LE 0.2%;
0.7% or 1/135 for vehicle). Excluding patients
who wore contact lenses during treatment,
0.6% (4/624), 1% (3/304), and 6.7% (11/164)
of subjects receiving LE, vehicle, and PA
experienced an IOP elevation. The authors
concluded that the suspension formulations of
LE 0.2% and 0.5% had a low propensity to cause
clinically significant IOP elevations. For the
purpose of this review, the same criterion of
C10 mm Hg above baseline is used to define
clinically significant IOP elevation unless
otherwise specified. Where available, data on
IOP elevations of C5 mm Hg are also reported.
Several new ophthalmic formulations of LE
have been approved for topical ophthalmic use
following Novack et al.’s meta-analysis [34]. LE
is now commercially available in the USA as an
ointment (Lotemax ophthalmic ointment 0.5%;
Bausch ? Lomb), a gel (Lotemax ophthalmic gel
0.5%; Bausch ? Lomb), and in combination
with tobramycin (Zylet LE 0.5% and
tobramycin 0.3% ophthalmic suspension;
Bausch ? Lomb). The efficacy of LE
formulations in the treatment of ocular
inflammatory conditions including the
treatment of ocular pain and inflammation
following cataract surgery, uveitis, and
seasonal allergic conjunctivitis and
blepharokeratoconjunctivitis has been
demonstrated in randomized controlled trials
and is the subject of several recent reviews
[35–37]. This article summarizes published data
to date on the safety of LE in the treatment of
numerous ocular inflammatory conditions,
with a specific focus upon IOP effects.
METHODS
A literature search was conducted for English
language articles using PubMed, Embase, Biosis
Previews, and Medline, using ‘‘loteprednol
etabonate’’ as the single search term, with no
time limitations through December 2015.
Clinical studies that report original
quantitative data on the impact of LE on IOP
were identified and reviewed. In addition,
relevant conference abstracts were included
where the data were not available in full
manuscript form. A brief summary of early
clinical trials that characterized the safety of
LE when used in the treatment of ocular
inflammation is followed with a
comprehensive review of additional safety data
on LE from studies published since the
meta-analysis by Novack et al. [34]. Finally, we
calculated the cumulative incidence of
clinically significant elevations in IOP, defined
as C10 mm Hg, with short-term or long-term
administration of LE across all relevant clinical
studies to date. The overall elevations in IOP
with the use of LE compared to vehicle,
dexamethasone, or PA were calculated from
head-to-head studies. Incidence rates were
based on the safety population (i.e., those
subjects that instilled study drug) wherever
reported. Significant differences (P\0.05)
between groups were determined using a
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two-tailed Z test with Yates correction using
SigmaPlot 11.0 (Systat Software, Inc.).
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
LE SUSPENSION IOP SAFETY
PROFILE: EARLY PIVOTAL TRIALS
Tables 1 and 2 provide a summary of all LE
studies cited in the review, categorized by
treatment duration (i.e., short term B28 days
and long term ]28 days). The effect of LE on
IOP was evaluated in randomized,
double-masked, vehicle-controlled studies
performed for the initial marketing approval
of LE in the USA. Two trials evaluated the safety
and efficacy of LE ophthalmic suspension 0.5%
administered four times a day for 2 weeks in
controlling postoperative inflammation and
pain after cataract surgery. One of the studies
reported no clinically significant elevation of
IOP (C10 mm Hg) in the LE treatment group
[26], while the other found a clinically
significant, yet transient IOP increase in 3% of
LE-treated patients [33]. The efficacy and safety
of LE 0.5% was compared to that of PA 1% (Pred
Forte, Allergan, Irvine, CA, USA) in patients
with acute anterior uveitis in two clinical trials
[27]. In the first study, medications were
administered up to eight times daily initially
and continued at a reduced frequency for up to
42 days, while in the second study, medications
were administered up to 16 times daily initially
and continued at a reduced frequency for up to
28 days. In both studies, the safety profile of LE
was more favorable with fewer incidences of
IOP increase C10 mm Hg (overall 1/115) than
the PA group (overall 7/121). Dell et al. [29, 30]
assessed the efficacy and safety of LE 0.5% and
0.2% ophthalmic suspensions administered
four times daily in the treatment of seasonal
allergic conjunctivitis in two clinical studies
conducted over a period of 6 weeks. None of the
LE-treated patients in the studies developed a
clinically significant IOP elevation, while
between 4% and 10% of LE patients had an
elevation of C6 mm Hg versus 1–7% of
vehicle-treated patients at each study visit
with LE 0.5%. In addition, Shulman et al. [32]
observed no difference in the incidence of
clinically significant IOP elevations between
the LE 0.2% (l/67) and vehicle (1/68) groups
during 6 weeks of treatment (four times daily
regimen) in a randomized, controlled
multi-center study of 135 patients with
seasonal allergic conjunctivitis. The safety and
efficacy of LE 0.5% applied four times daily for
6 weeks in patients with contact lens-related
giant papillary conjunctivitis were assessed in
two clinical trials [28, 31]. A transient IOP
elevation C10 mm Hg was observed in 3% and
7% of LE-treated patients, while there was no
IOP elevation in the vehicle-treated groups in
the two studies. Using the criterion of
C6 mm Hg, 15% and 25% of LE-treated
patients compared to 4% and 10% of
vehicle-treated patients were observed to have
an elevation in IOP in the two studies. Patients
were permitted to continue to wear their lenses
during these trials, and therefore concomitant
use of LE with contact lenses may slightly
increase the risk of IOP elevations, as is the
case for other corticosteroids. Thus, a presumed
depot effect should be considered when
prescribing LE to contact lens users or patients
using a therapeutic bandage contact lens.
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LE SUSPENSIONS: IOP DATA
FROM MORE RECENT STUDIES
Multiple studies evaluating the safety and
efficacy of LE have been reported in the
literature since the publication of the early
pivotal trials, both studies with short-term
treatment (summarized in Table 1) and studies
requiring long-term treatment for ocular
inflammation following various surgical
procedures and dry eye disease (DED;
summarized in Table 2).
Cataract and Refractive Surgery
Comparative studies of LE suspension 0.5% and
other anti-inflammatory agents support earlier
findings that LE 0.5% has a low impact on IOP
when used for postoperative inflammation and
pain following cataract surgery. Lane and
Holland [38] compared the effects of LE 0.5%
and PA 1.0% (Pred Forte), administered four
times daily for 3 weeks, on postoperative
inflammation in a multi-center,
investigator-masked, randomized study in 88
patients after routine cataract surgery.
Throughout the 3-week follow-up, LE-treated
patients had a lower mean elevation of IOP than
patients treated with PA, though the difference
was not statistically significant. None of the
LE-treated patients developed clinically
significant IOP elevation, while one PA-treated
patient had a [10 mm Hg elevation in IOP
7 days after surgery.
Two prospective studies evaluated the
comparative efficacy and safety of LE
ophthalmic suspension 0.5% and topical
nonsteroidal anti-inflammatory drugs (NSAIDs)
in reducing inflammation after uncomplicated
cataract surgery [39, 40]. In an open-label study,
Bannale et al. [39] showed similar tolerability
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sodium 0.03% administered postoperatively
four times daily for 4 weeks, with no reports of
clinically significant IOP elevation in patients
receiving either treatment (n = 20). Holzer et al.
[40] compared the safety and efficacy of LE with
those of ketorolac tromethamine 0.5% in a
randomized double-masked study of 60 patients
undergoing cataract surgery. The
anti-inflammatory agents were administered
four times a day for the first week (starting
24 h after surgery) and then two times a day for
a total of 30 days. There were no differences in
mean IOP between the two treatment groups at
any time, with mean [±standard deviation (SD)]
IOP ranging from 12.0 ± 3.8 to
15.1 ± 3.8 mm Hg in the LE group and
13.7 ± 3.1 to 16.0 ± 2.8 mm Hg in the
ketorolac group. The highest IOP readings (23
and 24 mm Hg) were measured in two patients
in the LE group 1 month postoperatively;
however, these patients had baseline
(preoperative) IOP values of 25 and 24 mm Hg,
respectively.
The comparative safety of LE suspension
0.5% and fluorometholone (FML) 0.1% were
evaluated in patients undergoing
photorefractive keratectomy (PRK) in a
retrospective analysis of 579 eyes of 316
patients [41]. All patients had PA 1% instilled
four times daily in the first postoperative week,
followed by either PA 1% two times daily for
3 weeks, followed by LE 0.5% twice daily for
1 month and then once daily for 1 month
(12 weeks in total), or PA 1% four times daily
for three more weeks followed by FML 0.1%
three times daily for a month, tapered by one
drop per day per month (16 weeks in total). The
results showed LE suspension 0.5% and FML
0.1% were both associated with a low incidence
of elevated IOP (fewer than three patients at
months 2 and 3) when incorporated into
treatment protocols for the prevention of
post-PRK haze.
High-Risk Groups
The potential for a corticosteroid to raise IOP is
proportional to the duration of treatment [7,
19]. IOP increase is, therefore, a particular
concern for patients who require prolonged
use of topical corticosteroids. Post-keratoplasty,
patients are at high risk for IOP increases,
because they require chronic use of topical
corticosteroids as prophylaxis against allograft
rejection. For those who have undergone
corneal transplantation for keratoconus or
Fuchs endothelial dystrophy, the incidence of
corticosteroid-induced IOP elevation
C5 mm Hg has been reported to be more than
60% within 4 years [42]. LE has been shown to
successfully reverse mean IOP elevation induced
by PA treatment, while preventing allograft
rejection in patients after corneal
transplantation [43]. In a retrospective
analysis, 30 corneal transplant patients who
developed IOP increases to[21 mm Hg with the
use of PA 1.0% (average dose of 2.4 times daily)
were switched to LE suspension 0.5% at doses
averaging 2.3 times daily at 3 weeks of use
tapered down to 1–2 times daily by week 39
[43]. There was a lowering of mean IOP from
31.1 to 18.2 mm Hg (P = 0.0001) with LE
treatment which averaged 21.6 weeks, with a
mean percent IOP reduction of 32.6% at week 3
and 44.9% at week 39.
The above findings are consistent with
previous findings in subjects known to be
corticosteroid responders. In a randomized,
double-masked, crossover study where 19
known steroid responders received either LE
suspension 0.5% or PA 1.0% four times daily for
42 days, followed by a washout period of at least
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14 days before crossing over to the other
treatment, LE suspension 0.5% demonstrated
less propensity to cause an IOP increase
compared with PA 1.0% [44]. Subjects
experienced increase of 4.1 mm Hg while on
LE treatment, which was not a significant
difference from baseline, whereas treatment
with PA resulted in significant mean IOP
increases from baseline at all follow-up visits
(mean IOP elevations of 5.9, 7.7, and
9.0 mm Hg at days 14, 28, and 42,
respectively; P\0.05 for all). By the Armaly
classification [14], only one subject (7.1%) in
the LE group was identified as a high responder
([15 mm Hg increase) by day 42, compared
with four subjects (30.8%) in the PA group.
Dry Eye Disease
DED is now widely recognized as having an
ocular surface inflammatory component, and
suppression of inflammation has been shown to
reduce the signs and symptoms of this chronic
condition [45–47]. Topically administered LE
may have a role in anti-inflammatory therapy
for DED and several studies evaluating the
efficacy of LE suspension for this condition
have also investigated the ramifications on IOP
[48–54]. A pilot clinical trial compared the
efficacy and safety of LE 0.5% to vehicle for
reduction of clinical inflammatory signs and
symptoms in patients with DED and delayed
tear clearance [48]. Sixty-six patients were
randomly assigned to receive either LE
suspension 0.5% or vehicle four times daily for
4 weeks; none of the LE-treated patients
developed clinically significant IOP elevation
during the study. In an open-label masked study
of 50 patients with moderate to severe DED,
Villani et al. [49] demonstrated that there was
no clinically significant IOP elevation during a
regimen of LE suspension 0.5% administered
four times a day for 4 weeks.
Recent clinical studies suggest that long-term
administration of LE suspension 0.5% has
minimal effect on IOP when used in the
treatment of inflammation associated with
DED [50–54]. In a randomized, controlled
clinical trial of dry eye patients who had
undergone hematopoietic stem cell
transplantation, there was no IOP elevation
C10 mm Hg over baseline at any study visit in
either LE-treated (76 eyes of 38 patients; treated
twice daily) or cyclosporine A-treated eyes (74
eyes of 37 patients; treated twice daily) over a
period of 12 months [50]. Likewise, Sheppard
et al. [51] also reported no significant IOP
elevation (defined as two consecutive visits
with an IOP increase of 6 mm Hg above
baseline) in 36 patients with chronic dry eye
pretreated with LE 0.5% twice a day for
2–16 months, followed by concurrent
treatment with LE and cyclosporine A for
3–6 months. In a more recent prospective,
multi-center clinical study also reported by
Sheppard et al. [52], 112 patients with DED
were randomly assigned to treatment with
either LE (n = 57) or artificial tears (n = 55)
four times per day for 2 weeks, followed by
topical cyclosporine A twice per day with either
LE twice per day or artificial tear twice per day
for an additional 6 weeks. Mean IOP did not
increase from baseline with either treatment,
nor did it differ between the two groups. Three
LE-treated patients had an IOP increase,
compared with two in the artificial tear group
(degree of increase not reported). Jung et al. [53]
compared long-term (2 years) outcomes of LE
0.5% and FML 0.1% (both administered twice
daily) for severe dry eye associated with
Sjo¨gren’s syndrome in a retrospective analysis.
There were no significant increases in mean IOP
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in either treatment group (LE: n = 66; FML:
n = 67) over the course of the study and no
patient required IOP-lowering medication. At
24 months, 4 patients treated with LE (6.1%)
versus 9 treated with FML (13.4%) had an IOP
elevation of[2 mm Hg compared with baseline.
In these patients, those treated with LE had a
lower mean IOP than the ones treated with FML
(15.0 ± 0.8 vs. 16.5 ± 1.1 mm Hg, P = 0.04). Lee
et al. [54] reported a randomized controlled trial
of LE suspension 0.5% used four times daily
along with eyelid scrubs and warm compresses
in 34 patients with moderate or severe
meibomian gland dysfunction. During the
2-month treatment period, no cases of
clinically significant IOP increase were
observed.
Ocular Allergy
A number of studies corroborate data obtained
in the pivotal trials indicating that LE
suspension 0.2% is safe in the treatment of
allergic conjunctivitis. Gong et al. [55] reported
that LE 0.2% was comparable to olopatadine
0.1% in efficacy and safety in 300 Chinese
patients with seasonal allergic conjunctivitis. In
this investigator-masked, parallel-group study,
patients were randomized to either LE
suspension four times a day or olopatadine
twice a day for 15 days. No clinically significant
IOP elevation occurred with either treatment,
while nine patients in the LE 0.2% group and
four patients in the olopatadine groups
experienced an increase in IOP of C5 mm Hg.
LE 0.2% also demonstrated favorable
long-term safety and tolerability in patients
with allergic inflammation. In a retrospective
study of 159 patients with seasonal and
perennial allergic conjunctivitis, Ilyas et al.
[56] found no instances of IOP elevation
(defined as [5 mm Hg above baseline) with
continuous use of LE 0.2% (1–4 times daily)
for more than 12 months. Oner et al. [57]
recently evaluated the efficacy and safety of LE
suspension 0.5% compared with PA 1.0% and
FML 0.1% in a parallel randomized trial in
60 patients with vernal conjunctivitis. Both PA
and LE were more effective than FML in
reducing the symptoms and signs of vernal
conjunctivitis when administered four times
daily for 28 days. However, there was a
significant elevation of mean IOP in the PA
group after day 3 (P\0.001), which remained
elevated (P\0.001) even after three patients
were discontinued because of IOP increases.
One study and a case report have associated
short-term use of LE suspension 0.2% with
elevations of IOP. In a randomized,
double-masked study of 20 patients with
seasonal or perennial allergic conjunctivitis
undergoing a conjunctival allergen challenge,
Berdy et al. [58] identified a small but significant
increase in mean IOP (mean ± SD:
1.6 ± 2.08 mm Hg, P\0.001) following a
14-day treatment period of LE 0.2% four times
daily. Lu et al. [59] reported the case of a
29-year-old male Asian/Pacific Islander whose
IOP increased to 50 mm Hg in both eyes after
receiving topical LE 0.2% (four times a day) for
3 days for chronic red eye presumed to be
associated with soft contact lens wear. What is
notable about this case is the patient’s young
age and Asian descent; both considered risk
factors for steroid-induced IOP elevation [17,
18]. The patient’s IOP returned to normal upon
LE discontinuation, with no reported
glaucomatous damage.
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NEWER FORMULATIONS OF LE:
IOP-SAFETY PROFILE
LE/Tobramycin
In 2004, the FDA approved use of an LE
0.5%/tobramycin 0.3% (LE/T) suspension for
corticosteroid-responsive inflammatory ocular
conditions where superficial bacterial ocular
infection or a risk of bacterial ocular infection
exists. In a randomized, double-masked trial of
306 healthy volunteers treated with LE/T or
dexamethasone 0.1%/tobramycin 0.3% (DM/T;
TobraDex, Alcon, Fort Worth, TX, USA) four
times daily for 4 weeks, the DM/T group had an
increase in mean IOP from baseline at all study
visits (P\0.0001), whereas there was no
significant elevation with LE/T (P[0.61).
More subjects in the DM/T group (11 subjects,
7.48%) experienced IOP elevations C10 mm Hg
than in the LE/T group (three subjects, 1.95%;
P = 0.028) [60]. Thanathanee and colleagues
[61] compared the safety of LE/T and DM/T in
a randomized controlled study in 32 patients
undergoing PRK. The patients were randomized
to receive LE/T or DM/T four times daily for
1 month after surgery. Consistent with previous
findings that LE is safe for routine postoperative
treatment after PRK, one patient receiving LE/T
and three patients receiving DM/T experienced
an IOP increase C5 mm Hg from baseline
(P = 0.60). The IOP returned to normal within
1 month in these patients after discontinuation
of treatment.
Several studies have examined the clinical
safety of LE/T suspension compared with DM/T
in the treatment of blepharokeratoconjunctivitis,
an inflammatory eyelid margin disease with
secondary conjunctival and corneal
involvement. Rhee and Mah [62] reported that
neither treatment had a clinically significant
effect on mean IOP when administered twice
daily for 3–5 days in a controlled single-center
study in 40 patients. White and colleagues [63]
compared the safety of LE/T and DM/T in 276
patients in a randomized, investigator-masked,
parallel-group, multi-center study using the
recommended regimen of four times daily for
2 weeks. In contrast to the observation made by
Rhee and Mah [62], White and colleagues [63]
found a significant difference between LE/T and
DM/T in terms of the mean change from baseline
in IOP (-0.1 ± 2.2 vs. 0.6 ± 2.3 mmHg at day 7,
P = 0.03; -0.1 ± 2.4 vs. 1.0 ± 3.0 mmHg at
day 15, P = 0.01 for LE/T and DM/T,
respectively). Over the course of the study, 7.1%
of the LE/T-treated patients versus 14.4% of the
DM/T-treated patients had an increase in IOP of
5–9 mmHg. One patient in the DM/T group
experienced an IOP increase C10mmHg. These
results are in accord with another randomized
comparative multicenter clinical trial of 354
Chinese patients [64]. In this study, patients
receiving DM/T had a significantly greater IOP
increase from baseline at all follow-up visits as
compared to patients receiving LE/T, both dosed
four times daily for 2 weeks (P B 0.0186). Patients
treated with DM/T also had approximately twice
as many IOP elevations as compared to those
receiving LE/T of C5 mmHg (26% vs. 13%,
P = 0.0020) and C10 mmHg (3.4% vs. 7.3%,
P = 0.0958). Unlike the study by White et al.
[63], where no patients treated with LE/T had an
IOP increase C10 mmHg, six LE/T-treated
patients in the Chinese study experienced a
clinically significant IOP increase. This
difference was ascribed by the authors to
multiple factors including racial diversity and
patient age [64].
The effect of topical corticosteroids on IOP
elevation in children is largely unknown. One
study suggests that children have a lower rate of
ocular hypertensive response to topical
corticosteroids [65], while others have reported
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a more pronounced steroid-induced IOP effect
than in the adult population [66, 67]. The
results of two small randomized controlled
clinical studies suggest that short-term LE/T
therapy is safe in children (aged 0–6 years) with
eyelid inflammation or blepharoconjunctivitis
[68]. Patients with eyelid inflammation received
LE/T four times daily for 7 days followed by
twice daily for 7 days; those with
blepharoconjunctivitis received LE/T four
times daily for 14 days. Mean IOP and IOP
changes from baseline, assessed only in the lid
inflammation study, were not different between
LE/T and vehicle groups at any study visits
during 2 weeks of treatment. All study eye IOPs
were\30 mm Hg, and all changes from baseline
IOP were\10 mm Hg throughout the study.
LE Ointment
LE ointment 0.5% received FDA approval for
treatment of postoperative inflammation and
pain following ocular surgery based on two
randomized, double-masked, parallel-group,
vehicle-controlled clinical trials involving a
total of more than 800 cataract surgery
patients. An integrated analysis of data from
these two studies indicates that mean IOP was
consistently lower than baseline over the course
of the study in both treatment groups when
administered four times daily for 14 days
following surgery [69]. The incidence of
clinically significant IOP elevation did not
differ between the treatment groups (three
LE-treated patients and one vehicle-treated
patient).
In addition to postoperative management of
cataract surgery, LE ointment has been
proposed as part of the perioperative regimen
for surgical removal of pterygium [70, 71].
However, no IOP-safety data were identified in
the literature for this usage during this review.
LE Gel
The gel formulation of LE 0.5% was approved in
2012 for the treatment of postoperative pain
and inflammation following ocular surgery. LE
gel 0.5% was well tolerated and had a good
safety profile in comparison with vehicle in two
identical randomized, controlled clinical
studies in patients undergoing cataract surgery
[72, 73]. In each study (n = 407 and 406,
respectively), patients with anterior chamber
inflammation following cataract surgery were
randomized to LE gel or vehicle four times daily
for two weeks. In both studies, mean IOP
decreased over the treatment period in each
group, and only one LE-treated patient
developed a clinically significant elevation in
IOP in each study (one of which was not
considered related to the study treatment),
compared with 1 and 0 vehicle-treated
patients, respectively.
Post-approval studies on LE gel support the
safety and tolerability of LE gel 0.5% in treating
postoperative pain and inflammation following
ocular surgery. Abessi et al. [74] reported
equivalent effect of LE gel 0.5% and
difluprednate 0.05% on IOP when used in the
control of postoperative inflammation in
cataract patients. Both corticosteroids were
administered four times daily for 3 days prior
to and 1 week post-surgery, followed by twice
daily dosing for 1 week. No treatment-related
clinically significant IOP elevations were
observed and the two groups demonstrated no
difference in mean IOP.
Three studies evaluated the effect of LE gel
0.5% on IOP over longer-term use. Salinger et al.
[75] conducted a retrospective chart review of
laser-assisted in situ keratomileusis (LASIK) and
PRK patients (n = 96 and n = 108 patients,
respectively) treated with LE gel for control of
postoperative inflammation and pain. During
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the first postoperative week, LE gel was
prescribed most frequently as one drop
four times daily. The most common duration
of postoperative LE gel therapy was 7–14 days
for LASIK patients and 30 days or longer for PRK
patients. There were no IOP increases of
C10 mm Hg at any postoperative visit in the
LASIK patients, while two cases of clinically
significant IOP elevations were observed in the
PRK patients. Smaller elevations in IOP of
C5 mm Hg were observed in two LASIK
patients and 32 PRK patients over the course
of the study.
Price and colleagues [76] compared the
efficacy and safety of LE gel 0.5% and PA 1%
in preventing immunologic rejection episodes
after Descemet’s membrane endothelial
keratoplasty (DMEK) in a randomized
investigator-masked controlled trial. A total of
167 patients were randomized to LE gel or PA
four times daily for 2 months, followed by
three times daily for a month, twice daily for a
month, and once daily for 7 months. PA 1%
treatment was twice as likely (relative risk: 2.3,
95% confidence interval: 1.2–4.5, P = 0.016) as
LE gel to induce IOP elevation (defined as
IOP C 24 mm Hg or an increase C10 mm Hg
from baseline). In PA-treated eyes, a
significantly higher proportion (20%) of
patients had a clinically significant increase in
IOP as compared to LE gel-treated eyes (7.3%;
P = 0.013).
Finally, use of LE gel as either a monotherapy
or induction therapy prior to treatment with
0.05% cyclosporine emulsion (CsA) was
recently investigated in 102 patients with mild
or moderate DED [77]. Subjects were
randomized to a 12 week treatment with LE
gel alone (n = 36), LE gel instilled on weeks 1–4
and CsA instilled on weeks 2–12 (n = 33;
induction), or CsA alone (n = 33), all with
twice daily administration. Mean IOP in the
LE monotherapy group was not statistically
different from that in the CsA monotherapy
group (P C 0.07). At week 12, only one subject
in the monotherapy group had an IOP of
34 mm Hg bilaterally and one subject in the
induction therapy group had an IOP of




The incidence of IOP elevations from studies
which defined clinically significant IOP increase
as C10 mm Hg were pooled to provide an
aggregate rate of IOP elevation. Of all subjects
that received short-term LE treatment, 0.8%
(14/1725 subjects) had clinically significant IOP
elevations (Table 1; Fig. 2). With long-term LE
treatment, excluding those subjects known to
be wearing contact lenses during treatment, the
overall incidence of IOP elevation was 1.5% (21/
1386 subjects)—slightly higher than the 0.6%
incidence rate (4/624 subjects) reported by
Novack et al. [34] (Table 2; Fig. 2). When
pooling data from studies with vehicle or
active control groups, the cumulative
incidence of clinically significant IOP
elevation was similar to vehicle [0.6% (9/1407)
vs. 0.4% (6/1365), P = 0.646], but considerably
lower than those of patients treated with PA
[3.4% (10/291) vs. 11.3% (33/292), P\0.001] or
DM/T [1.8% (9/491) vs. 5.2% (25/485),
P = 0.008; Tables 1, 2; Fig. 3].
CONCLUSIONS
Evidence from published data indicates that
topical treatment with LE has minimal effect on
IOP when used in the treatment of a wide range
of ocular surface and intraocular inflammatory
Adv Ther (2016) 33:532–552 547
disorders, including ocular allergy, DED,
anterior uveitis, penetrating keratoplasty,
endothelial keratoplasty, and postoperative
pain and inflammation following ocular
surgery. In all studies, LE consistently
demonstrated a low propensity to elevate IOP,
regardless of formulation, dosage regimen, or
treatment duration, including in known steroid
responders. The topical C-20 ester corticosteroid
has consistently demonstrated a low propensity
to increase IOP even in known steroid
responders. This improved safety profile makes
LE therapy an advantageous treatment option
for ocular inflammation, especially in cases
where chronic use of a topical corticosteroid is
necessary, but limited by a higher risk for ocular
hypertension. That said, more head-to-head
studies comparing the newer formulations of
LE and other topical corticosteroids, especially
newer topical corticosteroids such as
difluprednate, are warranted to better
understand the relative safety of currently
available corticosteroid treatment options for
ocular inflammation.
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Fig. 2 Cumulative rates of clinically signiﬁcant IOP
elevation with loteprednol etabonate. Short-term
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